Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
ETF Daily News6d
Vertex Pharmaceuticals (VRTX) to Release Earnings on Monday
Vertex Pharmaceuticals Stock Down 0.0 % Shares of Vertex Pharmaceuticals stock opened at $439.62 on Monday. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The ...
Morningstar2d
Vertex Announces FDA Approval of JOURNAVXâ„¢ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
This press release features multimedia ... M.D., Chief Executive Officer and President of Vertex. “With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class ...